Page 17 - Read Online
P. 17

Fung et al.                                                                                                                                                         Antivirals in hepatitis B hepatocellular carcinoma

               Cancer Med 2014;3:390-6.                          Hepatol 2017; doi: 10.1111/jgh.13848
           93.  He L, Liu X, Zhao Y, Zhang S, Jiang Y, Wang X, Yang Z. Efficacy   102. Shim JJ, Oh CH, Kim JW, Lee CK, Kim BH. Liver cirrhosis stages
               of nucleot(s)ide analogs therapy in patients with unresectable HBV-  and the incidence of hepatocellular carcinoma in chronic hepatitis
               related hepatocellular carcinoma: a systematic review and meta-  B patients receiving antiviral therapy. Scand J Gastroenterol
               analysis. Dis Markers 2017;2017:7075935.          2017;52:1029-36.
           94.  Nagai H, Mukozu T, Matsui D, Kanekawa T, Kanayama M, Wakui   103.  Li ZQ, Hu CL, Yu P, Gu XY, Zhang JJ, Li H, Zhang HY, Lv J,
               N, Momiyama K, Shinohara M, Iida K, Ishii K, Igarashi Y, Sumino   Liu YM, Zeng QL, Yan JY, Yu ZJ, Zhang Y. The development of
               Y. Sorafenib prevents escape from host immunity in liver cirrhosis   hepatocarcinoma after long-term antivirus treatment of Chinese
               patients with advanced hepatocellular carcinoma. Clin Dev Immunol   patients with chronic hepatitis B virus infection: Incidence, long-
               2012;2012:607851.                                 term outcomes and predictive factors. Clin Res Hepatol Gastroenterol
           95.  Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, Xia F, Bi F, Li Q. A high   2017;41:311-8.
               baseline HBV load and antiviral therapy affect the survival of patients   104. Wang Y, Xiang X, Chen L, Cao Z, Bao R, Zhou H, Tang W, Lu J,
               with advanced HBV-related HCC treated with sorafenib. Liver Int   Lin L, Xie Q, Bao S, Wang H. Randomized clinical trial: nucleos(t)
               2015;35:2147-54.                                  ide analogues improved survival of CHB-related HCC patients
           96.  Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load   via reducing severity and progression of malignancy. Oncotarget
               predicts survival in hepatocellular carcinoma patients treated with   2016;7:58553-62.
               sorafenib. J Gastroenterol Hepatol 2015;30:1024-31.  105. Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS,
           97.  Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, Li S, Chen M.   Lee JH, Koh KC, Paik SW. Lamivudine versus entecavir for newly
               Antiviral therapy in the improvement of survival of patients with   diagnosed hepatitis B virus-related hepatocellular carcinoma. Gut
               hepatitis B virus-related hepatocellular carcinoma treated with   Liver 2016;10:939-47.
               sorafenib. J Gastroenterol Hepatol 2015;30:1032-9.  106. Yuan P, Chen P, Qian Y. Evaluation of antiviral therapy performed
           98.  Zhang P, Yang Y, Wen F, Wheeler J, Fu P, Li Q. Cost-effectiveness   after curative therapy in patients with HBV-related hepatocellular
               analysis of antiviral therapy in patients with advanced hepatitis B   carcinoma: an updated meta-analysis. Can J Gastroenterol Hepatol
               virus-related hepatocellular carcinoma treated with sorafenib. J   2016;2016:5234969.
               Gastroenterol Hepatol 2016;31:1978-85.         107. Xia BW, Zhang YC, Wang J, Ding FH, He XD. Efficacy of antiviral
           99.  Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of   therapy with nucleotide/nucleoside analogs after curative treatment
               viral status on survival in patients receiving sorafenib for advanced   for patients with hepatitis B virus-related hepatocellular carcinoma: a
               hepatocellular cancer: a meta-analysis of randomized phase III trials.   systematic review and meta-analysis. Clin Res Hepatol Gastroenterol
               J Clin Oncol 2017;35:622-8.                       2015;39:458-68.
           100.  Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van   108. Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues
               Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio   for hepatitis B virus-related hepatocellular carcinoma after curative
               A, Siakavelas S, Keskin O, Gatselis N, Hansen BE, Lehretz M, de   treatment: a systematic review and meta-analysis. PLoS One
               la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis   2014;9:e102761.
               K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA,   109. Yeh YC, Liu CJ, Kuo RN, Lai CL, Shau WY, Chen PJ, Lai MS.
               Lampertico P. The risk of hepatocellular carcinoma is decreasing after   Association of adjuvant antiviral therapy with risk of cancer
               the first 5 years of entecavir or tenofovir in Caucasians with chronic   progression and deaths in patients with hepatitis-B-virus-related
               hepatitis B. Hepatology 2017;66:1444-53.          hepatocellular carcinoma following curative treatment: a nationwide
           101. Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, Park S, Hwang   cohort study. PLoS One 2014;9:e102051.
               JS. Temporal improvement in survival of patients with hepatocellular   110.  Fung J, Lai CL, Seto WK, Yuen MF. Emerging drugs for the treatment
               carcinoma in a hepatitis B virus-endemic population. J Gastroenterol   of hepatitis B. Expert Opin Emerg Drugs 2016;21:183-93.































                           Hepatoma Research ¦ Volume 3 ¦ November 27, 2017                               293
   12   13   14   15   16   17   18   19   20   21   22